Anavex Life Sciences (AVXL) H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference summary

Key presentations and scientific insights

• Projected exponential growth of Alzheimer's cases, reaching up to 150 million by 2050, with cumulative care costs exceeding $20 trillion and significant caregiver burden.

• Highlighted blarcamesine (ANAVEX®2-73), an oral small molecule, showing superior safety and efficacy in early Alzheimer's compared to antibody therapies, and positive real-world evidence in Rett syndrome.

• Described a unique upstream neuroprotection mechanism via SIGMAR1 activation and autophagy, offering both therapeutic and preventative effects in animal models.

• Pipeline includes additional indications: Parkinson's, Parkinson's dementia, Rett syndrome, Fragile X, infantile spasms, Angelman syndrome, and schizophrenia, supported by international patent protection through 2030-2039.

• MRI data suggest blarcamesine may slow or halt brain atrophy in Alzheimer's, a key marker of disease progression.

Clinical development and regulatory updates

• Currently in submission stage for Alzheimer's, with ongoing and upcoming regulatory submissions in the U.S., Europe, and abroad, and ongoing discussions with authorities.

• Full phase II/III Alzheimer's data, mRNA biomarker, and RNA-seq analysis results expected by mid-2024; open-label extension study results to follow.

• Planning and ongoing trials for Parkinson's, Fragile X, and new rare diseases, with additional programs and publications anticipated.

• Recent FDA guidance aligns with trial design, focusing on cognitive endpoints for early Alzheimer's.

• Compassionate use of blarcamesine ongoing in Canada, UK, and Australia, with some patients on therapy for over four years.

Financial position and operational strategy

• Cash balance of $139.4 million as of March 31, 2024, with no debt and a projected runway of at least four years, supported by non-dilutive funding from advocacy groups and government grants.

• Fiscal year 2023 cash burn was $27.8 million, expected to be slightly higher in 2024.

• Expanding team with experienced hires in clinical pharmacology, regulatory affairs, and CNS drug development to support commercialization.

• Strong IP protection strategy and growing scientific advisory board to guide future development.

• Commitment to disciplined operational expenditures and maintaining a strong financial position for long-term growth.